Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Your Profile Become a Member/Get Newsletter Log In Contact Us
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Tech Corner
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by NARSAD, the Mental Health Research Association, and supported in part by a contract from the National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services
Research News
 
Light Shed on Ketamine’s Swift Antidepressant Action
30 August 2010. A mechanism by which ketamine produces a fast-acting antidepressive effect is proposed by researchers from Yale University School of Medicine...
 
How Nature and Nurture Form an Anxious Temperament
23 August 2010. Brain activity that correlates with anxious temperament may arise through different paths...
 
Fishing Expedition Yields Pro-neurogenesis Elixir for NPAS3 Mice
19 August 2010. Scientists on an optimistic fishing expedition, involving 1,000 small molecules and hundreds of mice, have caught a big one...
 
 
 
 
Spotlight

Drugs in Trials Updated
Hugo Geerts of In Silico Biosciences, who created and maintains the SRF list of Drugs in Clinical Trials for schizophrenia has sent in a few updates. Several new compounds have entered preclinical assessment (GLYX-13, NPSP156, NT69L, Cpd X), others have progressed to new stages of clinical trials (Lu AE58054, AL-108, loxapine, ORM12471, PF-2545920, JNJ-39393406), and one has been discontinued (Merck's neuropeptide Y antagonist MK0557, which was a candidate to treat cognitive symptoms in schizophrenia).
Forum Discussion: Antipsychotic Dosing: How Much, But Also How Often?
In the latest edition of Schizophrenia Bulletin, Gary Remington of the University of Toronto, Canada, and Shitij Kapur of King’s College London, U.K., pose several thought-provoking questions about antipsychotic dosing: What are effective alternatives to continuous antipsychotic drug treatment? Is the shift toward slow-release formulations wrong-headed? Should one invest in compounds with short half-lives? Let us know what you think....

In our Forum Discussion "journal club" series, the editors of journals provide access to the full text of a recent article. In this case, we thank the Schizophrenia Bulletin, not to mention Oxford University Press, for providing access to the full text of an article by Remington and Kapur. A short introduction by Gunvant Thaker of the Maryland Psychiatric Research Center and Deputy Editor of Schizophrenia Bulletin gets us started, and then it's up to our readers to share their ideas and insights, questions, and reactions.
Transcript of Live Discussion—Language and Schizophrenia
Debra Titone
The use of language can be a window, albeit still an opaque one, onto the (mal)function of the brain in schizophrenia. We held our first discussion of this topic 1 April 2010, and you can now read the transcript. The discussion was based on a special issue of the Journal of Neurolinguistics, edited by Debra Titone of McGill University, that covered the history, recent developments, and methodology of language research in schizophrenia. Please comment on the discussion or Titone's introductory article, reprinted through the generosity of Elsevier, as well as the other articles in the issue at the Live Discussion page.
Welcome to the Schizophrenia Research Forum!
Welcome to the Schizophrenia Research Forum website—a virtual community for science about schizophrenia and related disorders. Our Mission is to help researchers in their quest for causes, improved treatments, and better understanding of schizophrenia. Read more about ways to browse the site.
 
What's New

Comments - Posted 31 August 2010
Read remarks by Matthew J. Smith about Rimol LM et al.
PAPER: Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder.
 
Grants - Posted 31 August 2010
NIH Request for Applications: Scientific Meetings for Creating Interdisciplinary Research Teams in Basic Behavioral and Social Science Research (R13)
 
Grants - Posted 31 August 2010
NIH Request for Applications: Revolutionary Genome Sequencing Technologies – The $1000 Genome (R01, R21, R43/44)
 
Grants - Posted 31 August 2010
NIH Request for Applications: Improving Evidence-Based Mental Health Screening and Treatment for Persons with Mental Disorders in the Justice System (R01, R34)
 
Comments - Posted 31 August 2010
Read remarks by Kenji Hashimoto about Li N et al.
NEWS: Light Shed on Ketamine’s Swift Antidepressant Action
 
Jobs - Posted 30 August 2010
Behavioral Pharmacologist: Cerca Insights, Penang, Malaysia.
September 2, 2010
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark

We invite you to share your theories and other thoughts on our Journal Club: Cognition in Mouse Models of Schizophrenia Susceptibility Genes

New Schizophrenia Fact Sheet for Patients and Families

Research News: Neurosurgical Treatment for Depression

SZGene
AlzGene
MSGene
PDGene
An up-to-date collection of all published genetic association studies.
A community resource created by Jim Koenig, University of Maryland.
We invite your comments and suggested edits to these facts about schizophrenia.
Compiled by Angus MacDonald, S. Charles Schulz, and the Minnesota Consensus Group.
 
Watch NIH Videocasts!

To be announced.

Research Participants
Collaborators
Copyright © 2005- 2010 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright